Compare NGL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | NEO |
|---|---|---|
| Founded | 1940 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Precision Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2011 | 2008 |
| Metric | NGL | NEO |
|---|---|---|
| Price | $16.82 | $16.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 234.6K | ★ 2.4M |
| Earning Date | 05-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,156,159,000.00 | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.36 | $6.38 |
| 52 Week High | $18.80 | $16.92 |
| Indicator | NGL | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 64.60 |
| Support Level | $15.11 | $11.49 |
| Resistance Level | $18.00 | N/A |
| Average True Range (ATR) | 0.76 | 0.59 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 41.45 | 95.00 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.